Literature DB >> 29525690

Ulipristal acetate decreases transforming growth factor β3 serum and tumor tissue concentrations in patients with uterine fibroids.

Michał Ciebiera1, Marta Włodarczyk2, Małgorzata Wrzosek2, Aneta Słabuszewska-Jóźwiak3, Grażyna Nowicka2, Grzegorz Jakiel3.   

Abstract

OBJECTIVE: To evaluate and compare transforming growth factor β3 (TGF-β3) serum concentration in patients with uterine fibroids (UFs) without hormone treatment, treated with ulipristal acetate (UPA), and controls; to evaluate TGF-β3 concentrations in UF tissue in patients without hormone treatment and those treated with UPA; and to evaluate the correlations of age and body mass index (BMI) with TGF-β3 serum and UF tissue levels between the groups.
DESIGN: Retrospective cohort study.
SETTING: University teaching hospital. PATIENT(S): A total of 141 patients divided into three groups: UFs non-UPA, UFs, and UPA, controls. INTERVENTION(S): Medical history and examination, genital ultrasound scan, blood and tissue sampling, and measurement of TGF-β3 serum and tissue concentrations. MAIN OUTCOME MEASURE(S): Evaluation of the impact of UPA (3 months treatment), age and BMI on TGF-β3 serum and UF tissue levels. RESULT(S): The values of TGF-β3 serum and tissue concentrations statistically significantly differed between the non-UPA and UPA groups. The mean TGF-β3 serum concentrations were non-UPA group 32.24 ± 34.55 pg/mL, UPA group 10.88 ± 7.15 pg/mL, and controls 11.97 ± 10.30 pg/mL. The mean TGF-β3 tissue concentrations were non-UPA group 171.29 ± 91.81 pg/mg and UPA group 99.99 ± 60.63 pg/mg. Statistically significantly lower mean TGF-β3 serum and tissue concentrations were observed in patients treated with UPA. No statistically significant correlations between TGF-β3 concentrations and age or BMI were found. CONCLUSION(S): Reduction of serum and tissue TGF-β3 concentrations in UFs may be an important component of the effect of UPA on UF biology. Further research in this area is necessary.
Copyright © 2017 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Leiomyoma; selective progesterone receptor modulator; transforming growth factor beta 3; ulipristal acetate; uterine fibroid

Mesh:

Substances:

Year:  2018        PMID: 29525690     DOI: 10.1016/j.fertnstert.2017.11.023

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  4 in total

1.  Cross-talk between miR-29c and transforming growth factor-β3 is mediated by an epigenetic mechanism in leiomyoma.

Authors:  Tsai-Der Chuang; Omid Khorram
Journal:  Fertil Steril       Date:  2019-12       Impact factor: 7.329

Review 2.  Selective Progesterone Receptor Modulators-Mechanisms and Therapeutic Utility.

Authors:  Md Soriful Islam; Sadia Afrin; Sara Isabel Jones; James Segars
Journal:  Endocr Rev       Date:  2020-10-01       Impact factor: 19.871

Review 3.  The Role of Tumor Necrosis Factor α in the Biology of Uterine Fibroids and the Related Symptoms.

Authors:  Michał Ciebiera; Marta Włodarczyk; Magdalena Zgliczyńska; Krzysztof Łukaszuk; Błażej Męczekalski; Christopher Kobierzycki; Tomasz Łoziński; Grzegorz Jakiel
Journal:  Int J Mol Sci       Date:  2018-12-04       Impact factor: 5.923

Review 4.  Vitamin D and Uterine Fibroids-Review of the Literature and Novel Concepts.

Authors:  Michał Ciebiera; Marta Włodarczyk; Magdalena Ciebiera; Kornelia Zaręba; Krzysztof Łukaszuk; Grzegorz Jakiel
Journal:  Int J Mol Sci       Date:  2018-07-14       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.